Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9345-351166      Publish Date : Sunday, April 10, 2016 Visit : 1715

Intl. Congress form | International Congress Report | International Congress Report For Faculty | 28th Annual European Association of Nuclear Medicine Congress

28th Annual European Association of Nuclear Medicine Congress
The report of 28th Annual European Association of Nuclear Medicine Congress by Dr. Armaghan Fard
Application Code :
306-0215-0133
 
Created Date : Sunday, November 15, 2015 12:34:20Update Date : Wednesday, March 9, 2016 11:14:40
IP Address : 194.225.55.130Submit Date : Wednesday, March 9, 2016 11:14:48Email : armfard@yahoo.com
Personal Information
Name : Armaghan
Surname : Fard-Esfahani
School/Research center : School of Medicine (International Campus)
If you choose other, please name your Research center :  
Position : Professor
Tel : +98-218-8633333
Information of Congress
Title of the Congress : 28th Annual European Association of Nuclear Medicine Congress
Title of your Abstract : Radioioeine Retreatment or Wait for a Limited Time in Patients with Differentiated Thyroid Carcinoma with Negative Thyroglobulin and Antithyroglobulin, but Remained Thyroid Residue after Post-Surgery Radioiodine Ablative Therapy?
Destination Country : Germany
From : Saturday, October 10, 2015
To : Wednesday, October 14, 2015
Abstract(Please copy/paste the abstract send to the congress) : Thyroid cancer follow-up after total thyroidectomy and radioiodine ablation therapy is performed mainly by assessment of radioiodine whole body scan (131I-WBS), thyroglobulin (Tg), anti-thyroglobulin antibody (Anti-TgAb) levels and sonography. Considering there are a number of patients with negative Tg, Anti-TgAb and sonography, but with a remained thyroid residue, and there is a concern about prolonged therapeutic effect of radioiodine, the best therapeutic approach as to give another therapeutic I-131 dose, or wait for a limited time to get more I-131 therapeutic effect from the first dose, is evaluated in this paper. 
Materials and Methods:In this study, we enrolled the DTC patients with only thyroid remnant in 131I-WBS six months after first ablative therapy. Patients with detectable Tg, high Anti-TgAb, evidence of neck mass in sonography and evidence of local or distant metastasis were excluded. The patients were randomly placed in two groups: A group who received I-131 retreatment and those who did not (follow-up group). Then after six months, the clinical results of these two groups were compared by evaluating 131I-WBS, Tg, Anti-TgAb and sonography.Results:From 94 enrolled patients, 36 patients were in retreatment group and 58 patients were in follow-up group without retreatment. Both groups matched by the variables including age, sex, pathology, tumor size, capsular, vascular and lymphatic invasion. In 47.2% of the retreatment group 131I-WBS still showed thyroid remnant, while in 52.8% 131I-WBS became negative. These values for the follow-up group without retreatment were 65.5% and 34.5%, respectively (p=0.08). In retreatment group, six months after retreatment, 97.2% of patients still had Tg<1ng/ml and 2.8% showed Tg elevation (Tg>1ng/ml). In the follow-up group, after six months 96.6% of patients still had Tg<1ng/ml and 3.4% showed Tg elevation (Tg>1ng/ml) (p=0.857). In 94.4% of retreatment and 98.3% of follow-up group Anti-TgAb six months after retreatment was <100mIU/ml (p=0.304). Sonography results were also insignificant (p= 0.403).
Conclusion: In patients with undetectable Tg/Anti-TgAb and only thyroid remnant in the six- month post-ablation 131I-WBS, delay in prompt radioiodine retreatment may be considered, as due to continued ablative effect of radioiodine, about one-third of these patients may have a negative 131I-WBS in the next six-month study, consequently less patient and society radiation burden and less economical loss, with same clinical results will be achieved. 
Keywords of your Abstract : Thyroglobulin, Thyroid Cancer, Radioiodine therapy
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/27807/Forms/306/Acceptance abstract Hamburg 2015_4.pdf
The presentation : Poster
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/27807/Forms/306/چلد کتابچه کنگره هامبورگ_3.PDF
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/27807/Forms/306/Published abstract with code Hamburg 2015_3.pdf
Where has your abstract been indexed? : ISI
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : 5000
Delegates from which countries presented in the congress? : The organizer was European Association of Nuclear Medicine and delegates from the
most of countries all over the world such as Germany, Italy, Turkey, USA, UK, Poland,
Hungary, Sweden, Greece, France, Spain, Netherlands, China, India, Austria, Australia,
Denmark, Finland ......were presented in the congress
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : IAEA, WFNMB, SNM
What were the responses to your talking points? Were specific questions or concerns raised? : I presented my research works about the possible delaying treatment in DTC patients with undetectable Tg and negative WBS which was of interest of nuclear medicine physicians interested in therapeutic subject, and I answered the questions in this regard.
If you met staff members, please list their full names & positions. : r. Sirus Mirzaei and Dr. Mohsen Beheshti; Members of Scientific Committee, EANM-2015
Please inform us if there are any follow up actions we need to talk with the members of the congress : Providing more facilities for participation of professors in the international symposium and congresses will place our country in a better ranking among other countries in regard to number of lectures and posters, which will be honorous to our university and country. Also, the members of the congress had better provide a breif report of their experience and present it to their students/residents. Also, preparing a valuable paper related to the presented abstract should be followed.
Your experiences about the travel processes(Providing ticket, accommodation,...) : Travel process especially visa receiving and heavy expenses were cumbersome.
Please give a briefing of your own observations and outcomes of the congress: : Congress committees provided educational sessions including high level of Continuous Medical Education and workshops in addition to offering a venue for presenting new researches. Highly valued lecturers
presented the latest scientific knowledge in multidisciplinary joint symposia and in CME sessions.The latest achievements in clinical nuclear medicine, science and technology were discussed perfectly during the congress. The inter-field cooperation among nuclear medicine physicians, radiopharmacists and physicists was highlighted in this congress, leading to more valuable scientific results.